Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A O Johnson

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Diabetes, Obesity & Metabolism|April 25, 2007
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitusC Constance, S Westphal, N Chung, et al.
International Journal of Clinical Practice|December 15, 2005
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart diseaseV Barrios, N Amabile, F Paganelli, et al.
International Journal of Clinical Practice|February 19, 2009
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS studyM Farnier, M Averna, L Missault, et al.
Diabetes, Obesity & Metabolism|February 22, 2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsL A Leiter, D J Betteridge, M Farnier, et al.
The Journal of Cell Biology|December 1, 1996
Transferrin receptor containing the SDYQRL motif of TGN38 causes a reorganization of the recycling compartment but is not targeted to the TGNA O Johnson, R N Ghosh, K W Dunn, et al.
Cardiology|November 20, 2008
Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary eventP Brudi, J P Reckless, D P Henry, et al.
International Journal of Clinical Practice|September 30, 2008
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension studyD Lütjohann, K von Bergmann, W Sirah, et al.
Clinical Immunology and Immunopathology|July 1, 1982
Depressed natural killer cell activity in children with protein-calorie malnutritionL S Salimonu, E Ojo-Amaize, A I Williams, et al.
Diabetes, Obesity & Metabolism|March 18, 2011
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusC Reasner, L Olansky, T L Seck, et al.
International Journal of Clinical Practice|February 13, 2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE studyJ P D Reckless, P Henry, T Pomykaj, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Diabetes, Obesity & Metabolism|April 25, 2007
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitusC Constance, S Westphal, N Chung, et al.
International Journal of Clinical Practice|December 15, 2005
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart diseaseV Barrios, N Amabile, F Paganelli, et al.
International Journal of Clinical Practice|February 19, 2009
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS studyM Farnier, M Averna, L Missault, et al.
Diabetes, Obesity & Metabolism|February 22, 2011
Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trialsL A Leiter, D J Betteridge, M Farnier, et al.
The Journal of Cell Biology|December 1, 1996
Transferrin receptor containing the SDYQRL motif of TGN38 causes a reorganization of the recycling compartment but is not targeted to the TGNA O Johnson, R N Ghosh, K W Dunn, et al.
Cardiology|November 20, 2008
Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary eventP Brudi, J P Reckless, D P Henry, et al.
International Journal of Clinical Practice|September 30, 2008
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension studyD Lütjohann, K von Bergmann, W Sirah, et al.
Clinical Immunology and Immunopathology|July 1, 1982
Depressed natural killer cell activity in children with protein-calorie malnutritionL S Salimonu, E Ojo-Amaize, A I Williams, et al.
Diabetes, Obesity & Metabolism|March 18, 2011
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusC Reasner, L Olansky, T L Seck, et al.
International Journal of Clinical Practice|February 13, 2008
Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE studyJ P D Reckless, P Henry, T Pomykaj, et al.
Pageof 7